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T he majority of home blood pressure monitors(HBPM) are purchased by consumers without phy-sician recommendations or endorsement.1 Industry
developed the electronic HBPM in 1984 without the en-
dorsement of any hypertension society. The number of
HBPM in most affluent countries is increasing, resulting in
more BP data being presented to the treating clinician.
Home blood pressure digital monitor revenue in the US in
2001 is estimated to be $142.2 million and is projected to
grow 22% over the next 5 years, with 10% declining
aneroid monitor sales; however, office digital monitor
growth over the next 5 years is projected to increase 833%
(Erica Brown, Frost & Sullivan, personal communication,
August 22, 2001). Primary care physicians and hyperten-
sion specialists receive the HBPM data from our patients,
yet we often have not provided proper patient guidance for
their usage. How can we best use these electronic devices
to improve hypertension control in our patients?
We believe it is now time for hypertension specialists to
endorse the proper usage of home BP devices, with proper
instructions to both patients and their primary care physi-
cians, who see most of the hypertensive patients in the
world. Indeed, an ad hoc committee of the American
Society of Hypertension in 1995 concluded that “self-
monitoring of BP is encouraged for the majority of hyper-
tensive patients.”2
Modern electronic monitors measure BP using the os-
cillometric technique, which has been validated to corre-
late with the auscultatory technique in most patients with
regular heart rhythms.3 The mean BP is measured by the
same technique in all monitors. Using proprietary algo-
rithms, each manufacturer calculates systolic and diastolic
BP differently. Absolute pressure measurement differs be-
tween monitors by different manufacturers, due to the
difference in algorithms. When an artificial BP simulator
was used, differences between HBPM were 12/9 mm Hg
with pulse differences of 3 beats/min, whereas measuring
in two normotensive subjects and comparing to a single
model HBPM demonstrated differences of 4/7 mm Hg
with pulse differences of 2 beats/min.4,5 This is similar to
the difference observed between the standardized research
and casual clinical measurements. Systolic differences of
6 mm Hg and diastolic differences of 4–10 mm Hg have
been reported, with 42% of subjects being falsely labeled
hypertensive by casual clinical methods.6–8 There are
limited data regarding accuracy with patients with arrhyth-
mias, such as atrial fibrillation.9,10
The advantage of digital HBPM is patient ease in usage
compared to aneroid manometers with stethoscopes. In-
struction in proper electronic manometers usage should be
less than the 20–45 min required for aneroid manometers,
as proper auscultation is the most difficult portion of
accurate auscultatory BP measurement.11,12 A patient
handout that describes the purchase and proper usage of
HBPM was developed for improved patient education and
to save providers time.13 Common errors for all types of
BP measurement still need to be instructed against: proper
cuff size, rest period before measurement, and avoidance
of talking and crossing legs during the measurement. Pa-
tients should be instructed to use only upper arm HBPM,
and the healthcare provider should indicate the proper cuff
size to the patient. Patients should be specifically discour-
aged from purchasing finger and wrist models. Manual
HBPM are significantly cheaper (approximately $30–40)
than the models with the pump included (approximately
$55–130); however, the automatic pump models are easier
to use, especially in patients with hand arthritis.14–16
Manufacturers are required to pass calibration tests on
HBPM that have new algorithms. There are two major
reference standards that are used,17,18 and most manufac-
turers perform the tests necessary for both. These stan-
dards compare standardized auscultation to the test device
using multiple subjects. Before accuracy standards were
developed, the HBPM was usually found to be inaccurate;
however, increasingly more manufacturers are publishing
accuracy assessment data before marketing their devices.
The European Society of Hypertension said that the fol-
lowing HBPM passed both the United States and the
British standards: Omron HEM 713C, Omron HEM 722C,
Omron HEM 735C, and Omron HEM 737 Intellisense
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(Omron Healthcare, Vernon Hills, IL).19 Unfortunately,
many manufactured devices are sold using different names
(ie, the retail store name) and model numbers than the
published reports. According to the current guidelines,
devices sold using different names or numbers should be
subjected to separate validation. This confusing situation
hopefully will be corrected in the future, by labeling the
original name and number on the device or revalidating
the device.
There are no standard guidelines developed for the
assessment of HBPM accuracy after purchase. We feel
that manufacturers should provide guidelines for users in
their device instructions on the proper interval for calibra-
tion of the device. Many physicians instruct patients to
bring HBPM to their office and perform sequential BP
readings. The physician indicates accuracy if the readings
are “close.” This is very misleading, due to the inherent
variability of BP and the lack of published standards of
accuracy. Accuracy of the device is defined by both the
measurement of the accuracy to a calibrated pressure and
the accuracy in human subjects. There is no literature
regarding accuracy assessment based on a single subject;
the Association for the Advancement of Medical Instru-
mentation (AAMI) standard requires 85 subjects.
The individual algorithm of a HBPM will not change
with time, as it is imbedded within the software/computer
chips and a failure of the circuit board would not allow any
measurements. A malfunction of the pressure sensor may
result in undetected erroneous readings; however, the fre-
quency of this is uncertain. To test the pressure sensor one
should use a calibrated BP simulator (Bio-Tek Instru-
ments, Winooski, VT) directly attached to the HBPM;
however, a calibrated aneroid or mercury manometer can
be used. For the nonautomatic HBPM, a hemostat is
clamped across the tube connected to the inflation bulb, to
prevent deflation while testing at different levels (60, 90,
140, and 200 mm Hg). The automatic devices need to have
the automatic deflation mechanism disabled. In the Omron
devices this is done with a special male adapter, obtained
from Omron, and in the A&D Medical (Milpitas, CA)
LifeSource models it is done by turning the maximum
pressure switch repetitively up and down at least three
times and then immediately pushing the “on” button. Mod-
els manufactured by other companies have no available
mechanism for overriding the deflation device; however,
some HBPM are manufactured by Omron or A&D Med-
ical and are labeled by another retailer’s name.
One author’s (SAY) experience in testing patients’
HBPM over 2.5 years found an accuracy of 0.3 mm Hg
(2.3 mm Hg) for the 91 electronic HBPM with an overall
92% accuracy, as defined within 3 mm Hg. This is
similar to the pressure accuracy of 136 aneroid manome-
ters at our institution of 0.2  0.3 mm Hg with an overall
96% accuracy.20 There are no data as to the duration of
accuracy of the HBPM. AAMI standards require the de-
vice to maintain safety and performance characteristics for
10,000 full inflation-deflation cycles, however, actual us-
age will result in different stressors to the machines than
the standard testing. We suspect that a 5-year life span is
realistic.
The Treatment of Hypertension According to Home or
Office Blood Pressure (THOP) trial is currently testing the
hypothesis that antihypertensive treatment guided by self-
measured BP may by more beneficial to the patient than
treatment based on conventional BP measurement by the
doctor.21 Patients are asked to perform BP readings using
a device that has a printer (Omron HEM 705CP) and
measure the BP between 6 AM and 10 AM and between 6 PM
and 10 PM. The patient takes the first three readings in the
sitting position, followed by a single reading in the upright
position. Patients are instructed to measure and print these
readings the week preceding the visit to their physician.
The initial difference between the average daytime (10 AM
to 8 PM) ambulatory BP and HBP has been found to be
small (2.2/0.9 mm Hg) and similar to differences in other
studies.22 The final results of the THOP are expected to be
reported in late 2002.
The definition of adequate hypertension control differs
depending on whether the measurements were taken at
home or at the physician’s office. Home BP is usually 8/6
mm Hg less than office BP measurements.20 On the basis
of a meta-analysis of summary statistics of published
articles and a meta-analysis of data from individual sub-
jects, 135/85 mm Hg is likely to be the upper limit of
normal for self-measured BP, when the goal equivalent
office BP is 140/90 mm Hg.23 It is important to teach
primary care physicians that a home BP of 140/90 mm Hg
should be interpreted as uncontrolled hypertension.
How does the clinician use the HBPM after determin-
ing it is accurate and assuring that the patient is using it
correctly? The device is best used to help to control known
hypertension, not for the diagnosis of new hypertension.
We encourage all patients with hypertension to use
HBPM. Patients may be given charts to graph the read-
ings, with the expected normal range highlighted (Fig. 1).
Trends and averages of the measurements are easier to
appreciate in graphic form than randomly placed numbers
on the back of a shopping list. Patients having their med-
ication adjusted are told to measure their BP twice a day in
the morning and before dinner for 2 to 4 weeks, depending
on the medication. Stable hypertensives are told to monitor
BP on the first day of the month and more frequently if the
readings are elevated. The charts are faxed or mailed to the
physician’s office and necessary therapy adjustments are
performed, with the cycle repeated until adequate hyper-
tension control is achieved. Newer HBPM with memory
and optional computer links, although much more costly,
allow graphic display and statistical analysis of the data. A
new telecommunication service consisting of automatic
transmission of BP data over telephone lines, computer-
ized conversion into report forms, and weekly electronic
transmission of the reports to physicians and patients was
found to decrease BP by 5/2 mm Hg compared to usual
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care.24 This may eventually become the standard method
of hypertension monitoring.
The American College of Physicians/American Society
of Internal Medicine this year completed a questionnaire
to develop relative value units and possible future reim-
bursement for home monitoring review, potentially includ-
ing home BP and glucose monitoring. Reimbursement for
monitoring home BP therapy is long overdue and would
encourage patient usage of HBPM and potentially improve
compliance and hypertension control. Patients who use
HBPM often feel that they help them better cope with
disease and reassure them.25,26 Although there is a lack of
well-designed studies regarding the improvement in com-
pliance and control of hypertension and cost-effectiveness
with the usage of HBPM, some recent studies are posi-
tive.27 Based on an analysis in 1992, in the US an esti-
mated $300 million/year could be saved with the usage of
HBP monitoring.27 This savings would be much greater in
2001.
In summary, in recommending a sphygmomanometer
in every home as early as 1972, Burch observed:
It is not more possible to regulate BP medicine
elegantly for a patient with hypertension, without
home recording of BP than it is to regulate the dose
of insulin for a patient with diabetes mellitus without
checking his urine for glucose at home.28
If we are going to improve the treatment of hyperten-
sion, we need to rely on proper BP data obtained under
appropriate conditions and methods. Uniformly dismissing
the home collection of this data as not accurate is losing an
important additional tool to help our patient’s care.
Our “Age of Anxiety” is, in great part, the result of
trying to do today’s job with yesterday’s tools—with
yesterday’s concepts.29
To do good work, one must first have good tools.30
All tools may be improved, and we believe that the
necessary tools are already available. The First Interna-
tional Consensus Conference of Self-Blood Pressure Mea-
surement provided a complete overview of the state of
HBPM and noted that the HBPM was valuable for the
evaluation of hypertension treatment efficacy.31,32
Physicians treating diabetes have successfully lobbied
for home glucose monitoring and reimbursement for their
patients in the US. Because hypertension control is equally
FIG. 1. Patient handout to record the systolic and diastolic blood pressure with an “X.”
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important in this and other high-risk populations, we
would encourage hypertension societies to actively cam-
paign for hypertensive patient reimbursement for HBPM.
Physicians interpreting home BP data should also be re-
imbursed for this valuable procedure. We would further
recommend hypertensive societies’ accreditation and en-
dorsement of properly validated HBPM by a seal, similar
to the American Heart Association program. We should
advocate that all future HBP monitoring devices have
labels with the name and model number of the device that
was validated, rather than the name of the retailer selling
the device. HBPM should all have a standard method to
prevent autodeflation, allowing for office calibration, and
where purchased, a measuring strip to assure proper cuff
size should be available.
Although we have taken for granted that BP is accu-
rately being measured by the auscultatory method in phy-
sician’s offices and hospitals throughout the world, recent
clinical hypertension research has used electronic BP
monitors in addition to auscultation.33 Many hospitals
routinely use oscillometric machines for BP determina-
tions, and the clinical usage of mercury is being banned
throughout the world, resulting in the loss of our gold
standard. This change from auscultation to oscillometric
determination of BP in hospitals has occurred without the
agreement or recommendation of the American Society of
Hypertension or other physician organizations. Because
we now have developed appropriate standards for accurate
HBPM, we should not continue to ignore the utility of
HBPM in the treatment of hypertension, or passively
watch as the most important aspect of treating hyperten-
sion, accurate BP determination, is determined by others.33
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